Details for Patent: 8,481,489
✉ Email this page to a colleague
Title: | GH secretagogues and uses thereof |
Abstract: | The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject. |
Inventor(s): | Abribat; Thierry (St-Foy-les-Lyon, FR), De Villers; Andre (Outremont, CA), Chapdelaine; Alcide (Ile des Soeurs, CA), Allas; Soraya (Iles des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA) |
Assignee: | Theratechnologies Inc. (Montreal, CA) |
Filing Date: | Sep 26, 2008 |
Application Number: | 12/239,697 |
Claims: | 1. A method of improving cognitive function in a subject suffering from mild cognitive impairment, said method comprising administering to said subject: (a) (hexenoyl trans-3)hGRF(1-44)NH.sub.2; or (b) a composition comprising (hexenoyl trans-3)hGRF(1-44)NH.sub.2 and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein said cognitive function is thinking, reasoning, problem solving or memory. 3. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 is administered at a dose of about 0.0001 to 2 mg. 4. The method of claim 3, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 is administered at a dose of about 0.1 mg or about 1 mg. 5. The method of claim 4, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 is administered at a dose of about 1 mg. 6. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 or said composition is administered by an intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal or topical route. 7. The method of claim 6, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 or said composition is administered by a subcutaneous route. |